Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | HTR2C | P28335 | 1/20 | 0.36 |
| ▸ | CHRNB2 | P17787 | 11/20 | 0.33 |
| ▸ | CHRNB4 | P30926 | 11/20 | 0.33 |
| ▸ | CHRNA3 | P32297 | 11/20 | 0.33 |
| ▸ | CHRNA4 | P43681 | 11/20 | 0.33 |
| ▸ | CHRNA7 | P36544 | 10/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | CNR1 | P21554 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27209297 | 0.82 | RECQL (0.53) | RECQLHTR2CCHRNB2CHRNB4CHRNA3 | |
| SCHEMBL9906300 | 0.79 | CHRNB2 (0.43) | RECQLCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL24322396 | 0.77 | RECQL (0.69) | RECQLCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL17079072 | 0.72 | RECQL (0.43) | RECQL | |
| Hydrochloric Acid SCHEMBL17078796 | 0.70 | RECQL (0.42) | RECQL | |
| SCHEMBL1481267 | 0.70 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL18081172 | 0.70 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL2379324 | 0.70 | HTR2C (0.46) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL28949604 | 0.70 | HTR2C (0.46) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA4 | |
| SCHEMBL377976 | 0.70 | CHRNB2 (0.46) | HTR2CCHRNB2CHRNB4CHRNA3CHRNA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO LTD (CN) | 2025-12-25 | — | — | US | disclosed |
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | DANATLAS PHARMACEUTICALS CO., LTD. (CN) | 2024-05-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240140954-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP11B2, SDHA, CYP3A43 | RECQL 398/4885HTR2C 496/4885CHRNB2 3578/4885 |
| US-20250388589-A1 | TRICYCLIC HETEROCYCLIC DERIVATIVES, COMPOSITIONS AND USES THEREOF | CYP4A11, CYP11B1, CYP2D6 | RECQL 2903/4885HTR2C 488/4885CHRNB2 426/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.